Ribo's RBD1016 Receives Orphan Drug Designation to Fight Delta Hepatitis Virus Infection Ribo Life Science's RBD1016 has gained orphan drug status from the EMA for treating Delta hepatitis, improving treatment options for patients.

Ribo's RBD1016 Receives Orphan Drug Designation to Fight Delta Hepatitis Virus Infection #Sweden #Gothenburg #Ribo_Life_Science #RBD1016 #EMA_Orphan_Drug